Winship Cancer Institute of Emory University | Strategic Alliance Partners

Jason Romancik, MD, discusses the benefit of axicabtagene ciloleucel vs standard of care as a second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.

Nabil F. Saba, MD, FACP, expanded on efficacy data from a phase 2 trial investigating pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma and current challenges and safety concerns in selecting patients for evaluation.

A doublet regimen comprised of pembrolizumab and cabozantinib elicited encouraging responses in patients with recurrent metastatic head and neck squamous cell carcinoma, meeting the primary end point of a phase 2 trial.

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.

Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.

Suchita Pakkala, MD, discussed how treatments like tucatinib and fam-trastuzumab deruxtecan-nxki have widened the armamentarium for patients with brain metastases; the importance of enrolling these patients in clinical trials; and what future treatment sequencing might look like for this population.

Jonathon B. Cohen MD, MS, discusses the management of chronic lymphocytic leukemia with BTK inhibitors, updates in the treatment of acute myeloid leukemia, and how CAR T-cell therapy could improve patient outcomes in diffuse large B-cell lymphoma and mantle cell lymphoma.

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

Jane Lowe Meisel, MD, discussed the emergence of HER2-low as a new category in breast cancer, outlining the significance of the phase 3 DESTINY-Breast04 trial and the unique qualities of trastuzumab deruxtecan in the HER2-positive and HER2-low populations.

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

Jonathon B. Cohen, MD, MS, discusses the evolution of treating patients with additional comorbidities in chronic lymphocytic leukemia.

Suchita Pakkala, MD, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.

State of Science Summit- Breast Cancer: Chaired by Kevin Kalinsky, MD, MS

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

EGFR C797X mutations have become a leading mechanism of acquired resistance following treatment with the third-generation EGFR inhibitor osimertinib, outpacing MET amplification.

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.

Mehmet A. Bilen, MD, and a panel of renal cell carcinoma experts discuss the preferred treatment options for patients with intermediate-risk or high-risk advanced renal cell carcinoma and the clinical features that may influence their decisions.